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Abstract
The aim of this study was to investigate the effect of a single dose of prednisolone on (A) 
high-intensity interval cycling performance and (B) post-exercise metabolic, hormonal and 
haematological responses. Nine young men participated in this double-blind, randomised, 
cross-over study. The participants completed exercise sessions (4 × 4 min cycling bouts 
at 90–95% of peak heart rate), 12 h after ingesting prednisolone (20 mg) or placebo. Work 
load was adjusted to maintain the same relative heart rate between the sessions. Exercise 
performance was measured as total work performed. Blood samples were taken at rest, 
immediately post exercise and up to 3 h post exercise. Prednisolone ingestion decreased 
total work performed by 5% (P < 0.05). Baseline blood glucose was elevated following 
prednisolone compared to placebo (P < 0.001). Three hours post exercise, blood glucose 
in the prednisolone trial was reduced to a level equivalent to the baseline concentration 
in the placebo trial (P > 0.05). Prednisolone suppressed the increase in blood lactate 
immediately post exercise (P < 0.05). Total white blood cell count was elevated at all time-
points with prednisolone (P < 0.01). Androgens and sex hormone-binding globulin were 
elevated immediately after exercise, irrespective of prednisolone or placebo. In contrast, 
prednisolone significantly reduced the ratio of testosterone/luteinizing hormone (P < 0.01). 
Acute prednisolone treatment impairs high-intensity interval cycling performance and 
alters metabolic and haematological parameters in healthy young men. Exercise may be an 
effective tool to minimise the effect of prednisolone on blood glucose levels.
Introduction
Glucocorticoids (GC) are a naturally occurring catabolic 
steroid, produced by the hypothalamic–pituitary–
adrenal (HPA) axis and regulated by neuroendocrine 
and immune responses (1, 2). Synthetic forms of GC, 
such as prednisolone, are used primarily for anti-
inflammatory purposes in the treatment of numerous 
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acute and chronic illnesses and diseases (3, 4, 5). As 
much as 17% of the population are prescribed GC on 
an annual basis, indicating the substantial prevalence 
of GC administration (6).
GC are often used by athletes for their proposed 
ergogenic effects, which has resulted in the World Anti-
Doping Agency banning their use during competition. 
Several recent reviews suggest that short-term (>2 weeks) 
GC treatment likely has an ergogenic effect on exercise 
capacity and performance (7, 8). However, the effects 
of acute (single dose) GC administration are less clear, 
largely due to limited research. As such, it is important 
to determine the biological effects of acute GC treatment, 
not only for the potential effects on performance but also 
for the health implications associated with GC treatment.
GC administration at supraphysiological doses can 
result in severe systemic side effects. In severe cases of 
prolonged GC treatment, this can result in iatrogenic 
Cushing’s syndrome with skin thinning and bruising, 
reduced bone density, accumulation of central adiposity, 
skeletal muscle wasting and hyperglycaemia (9). The 
withdrawal of exogenous GC or minimisation of dose 
and duration of therapy are recommended to minimise 
GC-induced side effects (10). However, this is not always 
possible and as such additional pharmaceutical drugs are 
often prescribed to treat GC-related symptoms, which 
may lead to the development of further unwanted side 
effects (10). Emerging research from animal studies has 
demonstrated the potential for exercise to be a viable 
alternative for managing certain GC-induced side 
effects, including skeletal muscle atrophy and insulin 
resistance (11, 12, 13). Yet, there is little evidence in 
humans regarding the potential benefits of exercise to 
treat and manage the cardiometabolic side effects of GC 
treatment.
In men, chronic or long-term GC treatment is 
associated with a reduction in circulating testosterone 
concentrations attributed to the inhibition of the 
hypothalamic–pituitary–testicular (HPT) axis (14). 
Exercise is not thought to interfere with the diurnal 
rhythm of testosterone production (15), and there may 
be a short-term effect of exercise training to reduce 
metabolic clearance of testosterone (16). However, how 
acute administration of GC may modulate sex hormone 
responses to exercise in men is unclear.
Therefore, the primary aims of this study were (A) 
to determine whether a single dose of prednisolone can 
influence exercise performance during high-intensity 
interval cycling and (B) to investigate the effects of 
acute prednisolone administration on metabolic, 
haematological and hormonal outcomes and determine 
the response to high-intensity exercise.
Methods
This study is part of a larger study and as such a detailed 
description of the methodology is provided elsewhere (17, 
18). In short, nine healthy, recreationally active males 
(age: 27.8 ± 1.7 years; BMI: 24.4 ± 0.8; fasting blood glucose: 
4.7 ± 0.2 mmol/L, Mean ± s.e.m.) participated in this double-
blind, randomised controlled, cross-over study. The 
participants orally ingested either prednisolone (20 mg) 
or placebo (Avicel), 12 h prior to undergoing an acute 
exercise session. The second session (either prednisolone 
or placebo) was completed after a washout period of at 
least 1  week. The high-intensity interval exercise (HIIE) 
consisted of 4 × 4 min cycling bouts at 90–95% of peak heart 
rate, interspersed with 2-min recovery periods at 50–60% 
of peak heart rate. We, and others, have previously reported 
that this type of exercise elicits favourable improvements 
in glycaemic control, compared to moderate-intensity 
exercise (19, 20). The workload for the second session 
was continuously modified throughout the exercise to 
elicit the same heart rate achieved during the first session. 
Informed consent was obtained from each participant and 
the study was approved by the Victoria University Human 
Research Ethics Committee.
Blood samples were taken prior to exercise, 
immediately after exercise, and 30 min, 1 h, 2 h and 3 h 
post exercise. Blood glucose and lactate concentrations 
were analysed using YSI 2300 STAT Plus (Glucose & Lactate 
Analyser, Australia). White blood cell (WBC) counts, red 
blood cell (RBC) counts, haemoglobin and haematocrit 
concentrations were analysed with a Sysmex KX – 21N 
(Kobe, Japan). Serum testosterone and dihydrotestosterone 
(DHT) were measured by liquid chromatography mass-
spectrometry using a Xevo TQ-S (Waters Corporation, 
Milford, MA, USA) with prior liquid-liquid extraction 
using methyl tert-butyl ether. The lowest limit of 
detection of testosterone and DHT is 0.08 nmol/L. Serum 
oestradiol (E2) was analysed by liquid chromatography 
mass spectrophotometry following derivatisation 
with Dansyl Chloride. The lowest limit of detection is 
5 pmol/L. The between-run imprecision for LCMS analysis 
of testosterone, DHT and E2 over the analytical range is 
5–10%. Serum sex hormone-binding globulin (SHBG) 
was analysed on an Immulite 2000 (Siemens Healthcare 
Diagnostics Inc.) and luteinizing hormone (LH) on an 
Architect Analyser (Abbott Diagnostics).
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Statistical analysis
Data were checked for normality and analysed using 
Predictive Analytics Software (PASW, SPSS Inc.). 
Comparison of means was examined using a two-
way (Treatment × Time) repeated-measures ANOVA. 
For all significant interaction and main effects, a priori 
comparisons of means (baseline vs all post-exercise time-
points; placebo vs glucocorticoid for all time-points) were 
conducted using Fisher’s least significant difference test 
(P < 0.05). All data are reported as mean ± standard error 
of mean (s.e.m.) and all statistical analysis were conducted 
at the 95% level of significance (P ≤ 0.05). Trends were 
reported when P values were greater than 0.05 and less 
than 0.1. Effect sizes (ESs) were calculated using Cohen’s 
d equation.
Results
Exercise performance
Prednisolone did not significantly affect the work 
performed in the first bout of HIIE. In contrast, 
prednisolone significantly decreased the work performed 
in the final three HIIE bouts, the difference became greater 
with each subsequent set (ES: 0.22–0.41, Fig.  1). Overall, 
the total work performed during the exercise session was 
significantly lower with prednisolone compared to placebo 
(prednisolone: 206 kj; placebo: 217 kj, P < 0.05). As expected, 
HR was not significantly different between each set, 
with and without prednisolone, as each set was matched 
according to HR (all P > 0.05, ES: 0.03–0.14). However, the 
mean difference for the entire session was slightly higher 
(1.5 bpm, P < 0.05, ES: 0.1) following prednisolone (Fig. 1).
Blood glucose
Prednisolone ingestion caused a significant increase in 
blood glucose concentration at baseline, immediately 
following exercise and 30 min, 1 and 2 h after exercise, 
compared to placebo (ES: 0.55–2.19, Fig.  2A). Blood 
glucose concentration in the placebo trial was not 
significantly altered from baseline throughout the session. 
Three hours following exercise, blood glucose levels in 
the prednisolone session were equivalent to the glucose 
concentration in the placebo session (P > 0.05).
Blood lactate
The acute administration of prednisolone did not alter 
baseline blood lactate concentrations. The HIIE caused an 
increase blood lactate concentration with both treatments; 
however, the increase in lactate was reduced by 14% with 
prednisolone compared to the placebo (P < 0.05, ES: 0.55) 
(Fig.  2B). Blood lactate returned to baseline levels after 
1 h of recovery in the prednisolone session, but remained 
elevated above baseline for up to 3 h post-exercise in the 
placebo session (Fig. 2B).
Haematology
Due to machine technical difficulties which resulted in 
missing data, results for haematological variables are 
reported for seven participants only.
In comparison to baseline, whole blood WBC 
concentration was significantly increased immediately 
following exercise, 2 and 3 h after exercise, for both 
treatments (Fig. 3A). Compared to placebo, prednisolone 
caused a significant elevation in whole blood WBC counts 
at all time-points (P < 0.01, ES: 1.18–2.01).
The HIIE caused a significant increase in whole 
blood RBC, haemoglobin and haematocrit immediately 
post exercise for both treatments (P < 0.05, ES: 1.2–2.23) 
(Fig.  3B, C and D). With both treatments combined 
whole blood RBC count decreased below baseline levels 
at 1 h post exercise (P < 0.05). Similarly, haemoglobin 
and haematocrit concentrations were decreased below 
baseline levels for up to 1 h after exercise (P < 0.05), 
returning to baseline levels 2 and 3 h into recovery. 
Prednisolone had no significant effect on whole blood 
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Figure 1
Mean work output (Watts) (solid bars) and heart rate (HR) (striped bars) 
during the high-intensity cycling sets. Δ expressed as a percentage 
difference between treatments. **P < 0.01, *P < 0.05 prednisolone 
significantly different from placebo.
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RBC count, haemoglobin or haematocrit compared to 
placebo (P < 0.05, ES: 0–0.32).
Sex hormones
Serum concentrations of testosterone, DHT and SHBG 
increased immediately after exercise with both placebo 
and prednisolone treatments combined (Fig. 4A, B and E, 
P < 0.05). DHT and SHBG concentrations decreased below 
baseline levels 1 h following exercise, before returning 
to pre-exercise levels 3 h post exercise (Fig.  4B and E). 
Similarly, testosterone decreased below baseline levels 1 h 
into recovery and remained reduced at 3 h post exercise 
(Fig.  4A). E2 was significantly elevated above baseline 
concentrations 3 h after exercise, irrespective of treatment 
(Fig. 4C, ES: 0.46–0.82).
A trend was observed for higher LH at all time-points 
with prednisolone; however, the effect was not significant 
(P = 0.087, ES: 0.17–1.24) (Fig. 4D). A significant treatment 
effect was observed in the ratio of testosterone/LH, 
with prednisolone causing a reduction in the ratio of 
testosterone/LH at all time-points in comparison to 
placebo (Fig. 5A, P < 0.01, ES: 0.56–1.3). Prednisolone did 
not significantly alter the testosterone/E2 ratio (Fig. 5B).
Discussion
The major findings of this study are (A) a single dose 
of prednisolone decreases work capacity during HIIE at 
∼95% of peak HR in healthy young men; (B) prednisolone 
significantly elevates fasting blood glucose concentrations 
which is restored to baseline 3 h after HIIE; (C) exercise 
acutely affects WBC counts and sex hormones which 
persists up to 3 h after exercise, while prednisolone reduces 
the ratio of testosterone/LH.
There is a lack of evidence regarding the effect of acute 
(single dose) GC treatment during HIIE, despite short-
term GC treatment indicating an ergogenic effect (7, 8). 
We report a significant reduction in the work completed, 
at the same relative intensity during HIIE, with prior 
prednisolone ingestion. This finding corresponds with a 
previous study which reported that acute prednisolone 
ingestion (20 mg) increased VO2 during steady state 
cycling at 60% of VO2max, indicating an increased 
energy demand during submaximal exercise, which may 
indicate reduced exercise efficiency (21). In contrast, 
HIIE following an acute 4 mg dose of dexamethasone 
appears to have no effect on VO2 or HR (22). Similarly, 
single-dose prednisolone (20 mg) has no effect on time to 
exhaustion at intensities between 70 and 85% of VO2max 
(23, 24). Together, the current evidence indicates that 
acute prednisolone reduces exercise capacity, especially at 
higher intensities, when the metabolic demand is high. 
The mechanisms by which GC reduces exercise capacity 
are not clear, but may be related to the acute effect of GC 
on skeletal muscle protein signalling including aberrant 
anabolic and insulin signalling proteins (18), and/or 
impaired skeletal muscle microvascular blood flow 
(25), both known mediators of exercise capacity. The 
discrepancy between our findings and others that have 
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Figure 2
(A) Blood glucose, (B) blood lactate responses (means ± s.e.m.) 12 h post 
capsule ingestion (baseline), immediately post exercise (Post-ex) and 
throughout recovery: 30 min, 1 h, 2 h and 3 h with prednisolone and 
placebo treatment. *P < 0.05, **P < 0.01, ***P < 0.001 between 
prednisolone and placebo treatment. (a) Different from baseline values 
with prednisolone ingestion (P < 0.05). (b) Different from baseline values 
with placebo treatment (P < 0.05).
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reported improved exercise performance after short-term 
GC is equally unclear (26, 27, 28). It could be speculated 
that a single dose of GC elicits a perturbation in whole-
body homeostasis, including impaired glycaemic control 
as indicated by elevated fasting glucose and insulin. 
In contrast, longer duration GC treatment (albeit still 
short term) may promote compensatory mechanisms 
that are able to control this initial homeostatic insult, 
Figure 3
(A) White blood cell (WBC) count, (B) red blood cell 
(RBC) count, (C) haemoglobin (HGB), (D) 
haematocrit (HCT) responses (mean ± s.e.m.) 12 h 
post capsule ingestion (Baseline), immediately 
post exercise (Post-ex) and throughout recovery: 
1 h, 2 h and 3 h with prednisolone and placebo 
treatment. **P < 0.01 between prednisolone and 
placebo. #P < 0.05 difference from baseline values 
with treatments combined.
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Figure 4
(A) Testosterone (T), (B) dihydrotestosterone (DHT), (C) oestradiol (E2), (D) luteinizing hormone (LH), (E) sex hormone-binding globulin (SHBG) responses 
(mean ± s.e.m.) 12 h post capsule ingestion (Baseline), immediately post exercise (Post-ex) and throughout recovery: 1 h and 3 h with prednisolone and 
placebo treatment. #P < 0.05 difference from baseline values with treatments combined.
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which may reflect why some studies have reported normal 
fasting glucose and insulin after short-term GC treatment 
(28, 29). Further research is warranted to explore the 
effect of acute prednisolone on exercise capacity and 
performance during other exercises and sports and to 
investigate the potential mechanisms.
Chronic GC treatment is known to induce side 
effects including hyperglycaemia and the development 
of diabetes (30, 31). However, the effects of a single-dose 
GC on fasting and post-exercise blood glucose levels in 
healthy individuals are not clear, and some reported that 
prednisolone (20 mg) causes an increase in blood glucose 
concentrations at baseline (23, 24, 32), while others 
reported that it has no effect on blood glucose (21, 22, 33). 
The results from the current study confirms that a single 
dose of prednisolone significantly increases blood glucose 
levels.
Exercise is known to improve insulin sensitivity and 
glucose regulation in healthy individuals and people who 
live with chronic conditions, including insulin resistance 
and type 2 diabetes (34, 35). We report that prednisolone-
induced hyperglycaemia was restored to baseline levels 3 h 
after a single session of HIIE. It is possible that the restoration 
of glucose levels after exercise may, in part, be due to the 
degradation of the biological activity of a single dose of 
prednisolone over the course of time. However, previous 
studies have also reported restoration of glucose levels when 
cycling exercise (80–85% of VO2max) is performed as little 
as 2–3 h after prednisolone (20 mg) ingestion (23). These 
findings highlight the important role exercise can play in 
improving glycaemic control during GC therapy. The effect 
of exercise on blood glucose may depend on the dosage of 
GC administered. For instance, both 1 and 4 mg doses of 
dexamethasone increase blood glucose levels at baseline, 
however, normalisation of blood glucose with exercise at 
90% of VO2max occurs with only the 1 mg dose (32). It is also 
possible that the normalisation of glucose levels is intensity 
dependant. Exercise at 70–75% of VO2max has previously been 
reported to have limited effect on blood glucose response 
following prednisolone treatment (20 mg) (24). The current 
findings provide new evidence that acute HIIE may help to 
minimise the elevation in blood glucose concentration that 
occurs following GC treatment. However, further research 
is required to confirm these findings with respect to timing 
of exercise following ingestion of GC and identifying 
the mechanisms involved (i.e. improved glucose uptake 
by skeletal muscle, a reduction in hepatic glucose output 
or both).
To determine the influence of prednisolone on other 
exercise-mediated metabolic responses, we measured blood 
lactate and changes in blood haematology. Blood lactate 
significantly increased from resting levels in response to 
HIIE with both treatments. However, the lactate response 
was supressed in the prednisolone trial compared to the 
placebo, possibly a reflection of the significant reduction 
in work performed during the exercise session. This 
finding is in contrast to previous studies which reported 
that blood lactate was not altered with prednisolone 
(21, 23, 24) and dexamethasone treatment (22, 32). 
Furthermore, none of these studies reported a change in 
exercise performance, which supports the hypothesis that 
lactate was likely reduced in the current study due to the 
reduction in work completed. It is also possible that the 
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(A) Testosterone (T)/luteinizing hormone (LH) ratio, (B) testosterone (T)/
oestradiol (E2) ratio (mean ± s.e.m.) 12 h post capsule ingestion (Baseline), 
immediately post exercise (Post-ex.) and throughout recovery: 1 h and 3 h 
with prednisolone and placebo ingestion. **P < 0.01 between 
prednisolone and placebo.
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use of a long duration, HIIE protocol in the current study 
may, in part, explain the discrepancy in findings, given 
that lactate metabolism is crucial in sustaining intense 
exercise (36).
GC therapy is used as an immunosuppressive agent 
to treat autoimmune diseases. However, little research 
has been conducted to explore the immune response 
following GC administration and exercise. We report 
that acute prednisolone ingestion causes an elevation 
in total WBC count at baseline (12 h after ingestion), 
and throughout the 3-h recovery period following HIIE. 
Similarly, the short-term inhalation of fluticasone results 
in an increase in total WBC and neutrophils at baseline, 
with a further increase following high-intensity exercise 
(37). However, another study reported that lymphocyte 
concentration was reduced in a time-dependent manner 
following prednisone ingestion (38), suggesting that 
specific WBC subtypes may respond differently to exercise 
and GC ingestion, warranting further investigation.
Changes in RBC count, haemoglobin and haematocrit 
are reported to influence exercise performance 
predominantly through the contribution of oxygen to 
working muscles (39). Therefore, we investigated whether 
the decreased exercise capacity with prednisolone 
ingestion would coincide with changes in these variables. 
Although the RBC count, haemoglobin and haematocrit 
were altered following HIIE, there was no treatment effect 
of prednisolone suggesting alternative pathways are likely 
for the impairment of exercise capacity.
Given the potential of androgen-glucocorticoid 
interactions and the role of hormonal regulation for exercise 
performance and adaptation (40, 41), we explored the effects 
of single-dose GC treatment on circulating sex hormone 
concentrations before and after a single session of HIIE. We 
report that HIIE increased circulating androgens, namely 
testosterone and DHT, as well as SHBG concentrations. While 
DHT and SHBG returned to baseline levels during recovery, 
testosterone concentrations remain below baseline, 
suggesting a biphasic response of testosterone to HIIE. E2 
concentrations were stable during exercise and increased 
during recovery. The ratio of testosterone/LH is reduced in 
men after taking prednisolone consistent with evidence 
of testicular, or more specifically Leydig cell, dysfunction 
(42, 43). Prednisolone reduced the ratio of testosterone/LH 
across all time-points consistent with an effect to impair 
testicular Leydig cell function superimposed on the effect 
of exercise. This occurred in the absence of any evidence 
of altered aromatase activity as the ratio of testosterone/
E2 was unchanged (44). This acute effect of prednisolone 
on Leydig cell function is noteworthy. Chronic GC therapy 
has been associated with lower circulating testosterone 
concentrations without elevation of LH, attributed to 
suppression of central components of the HPT axis 
(14, 45, 46). Our findings suggest that impairment of Leydig 
cell function may also play a role in the action of GC on 
the HPT axis. Further studies are warranted to ascertain 
the effects of chronic GC administration on Leydig cell 
function, and whether GC use impacts on multiple levels 
of the HPT axis.
Testosterone treatment in younger and older men has 
an anabolic effect including increased muscle strength 
and performance (40, 41). The acute effect of exercise 
to increase testosterone, DHT and SHBG could reflect an 
element of haemoconcentration following exercise. The 
reduction in testosterone post exercise but not DHT or 
SHBG would be consistent with downregulation of the 
HPT axis in the setting of fatigue. Further studies would be 
needed to establish whether chronic GC administration 
and more sustained periods of exercise might jointly 
impact on the function of the HPT axis to the detriment 
of exercise capacity.
This study has several potential limitations; first, 
there is a relatively small sample size. This study was 
conducted as part of a larger, invasive study, and as 
such, recruitment was difficult (18). This study was 
adequately powered to compare changes in blood glucose 
from baseline to 3 h post exercise, between placebo and 
prednisolone, P < 0.05, effect size of 2.65; n = 9; power of 
99%, which was the main outcome of the project. We 
also identified a significant difference in watts between 
placebo and prednisolone; however, a post hoc power 
calculation (G*Power 3.1.9.2; two-tailed dependent t-test, 
alpha = 0.05) demonstrated that it was underpowered 
(effect size of 0.41; n = 9; power of 23%). As such, future 
studies should include a larger sample size to account 
for an adequate power. Second, due to the metabolic 
differences between males and females, only males were 
tested in this study. As such, and acknowledging the 
differences in reproductive physiology between males and 
females, the results may not be applicable to females. It 
will be important to conduct further research in females 
to identify whether GC treatment has a different effect. 
Furthermore, the participants in this study were young 
and healthy, and as such these findings are delimited to 
this specific population with further research require to 
explore the effects of GC ingestion and exercise in other 
populations. Finally, the participants were given access to 
water ad libitum, it is possible that some of the changes in 
the haematological outcomes may be due to alterations in 
plasma volume.
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In conclusion, a single dose of prednisolone decreases 
work performed during high-intensity interval cycling 
that suggests that acute GC administration does not 
act as an ergogenic aid, and in fact may reduce exercise 
performance. Prednisolone also increases basal blood 
glucose concentrations, impairs Leydig cell function and 
increases WBC count. Importantly, acute HIIE restores 
euglycaemia which may indicate HIIE as a potential 
treatment strategy for counteracting GC-induced 
hyperglycaemia. Whether HIIE training can reduce the 
serious metabolic side effects of chronic GC administration 
warrants further investigation.
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